Forgot your password?

Forgot your username?

database > company
Del Mar Pharmaceuticals
Biotech Specialty Pharma
1727 West Broadway Suite 400
Vancouver, BC V6J4W6 Canada
phone:(604) 317-7022
fax:(604) 608-5685
Symbol Private
Founded 2010
Employees 3
www.delmarpharma.com
Research Sector Biotech Specialty Pharma
Summary Description
Anti-cancer therapies in new, high-impact orphan cancer indications
Management
Jeffrey Bacha, B.Sc., M.B.A.; Dennis M. Brown, Ph.D.; William J. Garner, M.D.
Keywords
Cancer, Glioblastoma, GBM, Orphan Drug, Small Molecule, Del Mar Pharmacuticals, DelMar

Comment | Printable Version | Modify profile |
Updated: Feb. 06, 2012

Description
Del Mar Pharmaceuticals develops and commercializes proven anti-cancer therapies in new, high-impact orphan cancer indications in which patients have failed modern biologic therapy. VAL-083 is the Company’s lead drug candidate, and has been indicated by over 40 pre-clinical and clinical studies to be active against a wide range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. According to published data, approximately half of patients diagnosed with GBM will fail both front-line therapy with Temodar™ and second-line therapy with Avastin™; there are currently no approved treatments for such patients. VAL-083 benefits from a historical investment of over $50M by the National Cancer Institute, and is currently undergoing clinical trials for GBM patients. The drug is already approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors. This earlier-stage biotechnology company’s access to proprietary ChemState™ bioinformatics tools allows the expedient identification and advancement of potential drug candidates, thereby furthering shareholder value.
Products / Services
VAL-083: Phase II, GBM
VAL-083: Clinical, Orphan Cancers
VAL-083: NSLSC
DMP-001: Pre-IND
DMP-002: Pre-IND
Market / Customers
Del Mar's key customers are physicians treating end-stage cancers covered by orphan drug designations and pharmaceutical companies marketing lung cancer chemotherapeutics.
Competitors / Substitutes / Alternatives
Currently, there are no products approved for GBM following the failure of Avastin.
Strategy
Del Mar Pharma is developing new drug candidates targeting orphan cancer indications representing market opportunities in the US$100Ms in North America and potentially billions of dollars worldwide. The Company aims to develop products that will have a high impact in patient care and a high return for our investors.

In order to accelerate development timelines and reduce technical risk, Del Mar leverages existing clinical and commercial data from a wide range of sources. This business model has been well validated and demonstrated to position for investor exit with significant upside, even prior to commercialization.

Key elements of Del Mar's business strategy include:
Leveraging existing human clinical data to support new regulatory filings with the U.S. FDA, Health Canada and the European Medicines Agency (EMEA);
Advancing products into orphan drug indications where patients are failing modern biologic or targeted therapy in order to obtain a guarantee of market exclusivity, attractive reimbursement, and high-likelihood of accelerated product approvals;
Establishing new intellectual property around our product candidates, including use, manufacturing, chemical composition and mechanism patent claims;
Obtaining commercial drug product from existing commercial manufacturers to accelerate entry into human clinical trials and reduce development costs;
Investigating the molecular mechanism of drug candidates in order to establish additional patent claims and also to identify patients most likely to benefit from therapy (personalized medicine approach);
Commercializing products through a combination of direct marketing and collaborative partnerships. For example, target-marketing products to the small number of leading cancer centers in North America who specialize in the treatment of resistant orphan cancers and establishing sales and marketing partnerships for "large volume" tumor markets and in international markets including Europe & Asia;
Generating near-term revenue by leveraging opportunities in markets where our drug candidates are already approved or can be readily registered;
Operating on a "virtual" basis to minimize fixed-research costs while maintaining access to a highly-experienced and skilled workforce.
Funding
Del Mar Pharma has been funded by its co-founders to date. We are seeking $5M from new investors to support the clinical development of VAL-083.
Status
VAL-083 is currently approved for the treatment of CML and lung cancer in overseas markets. Del Mar Pharma has filed an IND with VAL-083 for a Phase I/II study in refractory GBM. Previous clinical research sponsored by the NCI demonstrated efficacy in this indication.